Organization
Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South)
2 abstracts
Abstract
A phase 1 dose expansion study of a first-in-class KAT6 inhibitor (PF-07248144) in patients with advanced or metastatic ER+ HER2− breast cancer.Org: National Cancer Center Hospital East, Chiba, Japan, Samsung Medical Center, Seoul, seoul, South Korea, NEXT Oncology, San Antonio, TX, National Cancer Center Hospital, Tokyo, Japan, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea,
Abstract
Palbociclib plus exemestane with GnRH agonist vs capecitabine in premenopausal patients with HR+/HER2- metastatic breast cancer: Updated survival results of the randomized phase 2 study Young-PEARL.Org: Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul National University Hospital, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Department of Hematology-Oncology,